APELA and autosomal dominant polycystic kidney disease: Interestingly, Elabela has recently been shown to be better than Ape13 in improving fluid homeostasis and in limiting renal dysfunction in various kidney diseases, such as diabetic nephropathy, autosomal dominant polycystic kidney disease, renal ischemia/reperfusion injury, renal fibrosis, and septic shock (Day et al., 2013; Lacquaniti et al., 2013; Zhang et al., 2013; Chen et al., 2017; Coquerel et al., 2017; O’Carroll et al., 2017; Huang et al., 2018; Zhang et al., 2018).